drugset / Trial / NCT00012337
ZD 1839 in Treating Patients With Metastatic Kidney Cancer
Treatment
Summary
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer.
Timeline
- Start
- 2001-01
- Primary completion
- —
- Completion
- 2004-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | — | Oral |